Canopy Growth Corporation (NASDAQ: CGC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
0.96
+0.04+4.40%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.63 | Insider Own | 35.13% | Shs Outstand | 422.15M | Perf Week | 3.23% |
| Market Cap | 167.32M | Forward P/E | - | EPS next Y | -0.07 | Insider Trans | -0.19% | Shs Float | 415.29M | Perf Month | -3.31% |
| Enterprise Value | 105.97M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 5.56% | Perf Quarter | -17.36% |
| Income | -98.94M | P/S | 0.75 | EPS this Y | 84.29% | Inst Trans | - | Short Ratio | 2.64 | Perf Half Y | -17.36% |
| Sales | 221.92M | P/B | 0.64 | EPS next Y | 26.67% | ROA | -23.56% | Short Interest | 23.09M | Perf YTD | -19.54% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -35.48% | 52W High | 2.48 -61.46% | Perf Year | -12.64% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -15.65% | 52W Low | 0.88 8.75% | Perf 3Y | -77.12% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -6.50% -12.99% | Gross Margin | 22.18% | Volatility | 4.64% 4.09% | Perf 5Y | -99.53% |
| Dividend TTM | - | EV/Sales | 0.48 | EPS Y/Y TTM | 84.15% | Oper. Margin | -49.88% | ATR (14) | 0.04 | Perf 10Y | -95.62% |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | Sales Y/Y TTM | 16.58% | Profit Margin | -84.76% | RSI (14) | 44.76 | Recom | 2.93 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.34 | EPS Q/Q | 61.39% | SMA20 | -1.76% | Beta | 0.84 | Target Price | 11.02 |
| Payout | 0.00% | Debt/Eq | 0.40 | Sales Q/Q | 15.56% | SMA50 | -6.18% | Rel Volume | 0.38 | Prev Close | 0.92 |
| Employees | 1,128 | LT Debt/Eq | 0.36 | Earnings | Aug 07 | SMA200 | -17.75% | Avg Volume | 5.43M | Price | 0.96 |
| IPO Date | Apr 07, 2014 | Option/Short | No / No | EPS/Sales Surpr. | -293.79% 31.50% | Net Debt/EBITDA | 1.35 | Volume | 2,037,422 | Change | 4.40% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Nov-10-25 | Upgrade | Benchmark | Sell → Hold | |
| Nov-10-25 | Upgrade | The Benchmark Company | Sell → Hold | |
| Mar-21-22 | Downgrade | Barclays | Equal Weight → Underweight | |
| Jan-06-22 | Reiterated | Alliance Global Partners | Hold | |
| Dec-21-21 | Downgrade | B of A Securities | Neutral → Underperform | |
| Dec-19-21 | Downgrade | Piper Sandler | Neutral → Underweight | |
| Nov-23-21 | Reiterated | Jefferies | Hold | |
| Nov-07-21 | Downgrade | Cowen & Co. | Outperform → Market Perform | |
| Aug-11-21 | Upgrade | Jefferies | Underperform → Hold | |
| Jun-03-21 | Reiterated | Desjardins |
Latest News
Jul-25-26
Jul-25-2610:30AM
Jul-24-26
Jul-24-2606:51PM
08:00AM
Jul-22-26
Jul-22-2607:01PM
10:01AM
Jul-21-26
07:30AM
Jul-20-26
Jul-20-2611:12AM
Jul-17-26
Jul-17-2605:30AM
Jul-15-26
Jul-15-2611:21AM
3 Canadian Marijuana Stocks For Better Investing And Trading 2026marijuanastocks.com
Jul-13-26
Jul-09-26
Jul-09-2610:01AM
Jul-08-26
Jul-07-26
Jul-07-2607:01PM
03:35PM
Company
Canopy Growth Corporation (CGC), alongside its affiliated businesses, specializes in the cultivation, marketing, and retail of both cannabis and hemp-derived products. These offerings are designed for both recreational consumption and therapeutic uses, with its primary commercial reach extending across Canada, the United States, and Germany. The company structures its operations into two main divisions: Global Cannabis and a diverse portfolio of Other Consumer Products. Its extensive product range features dried cannabis flower, various extracts and concentrates, infused beverages, edible gummies, and vape cartridges. Canopy Growth distributes these items under numerous well-known brands, such as Tweed, 7ACRES, Martha Stewart CBD, and Spectrum Therapeutics, among others. Originally founded as Tweed Marijuana Inc., the enterprise adopted its current name, Canopy Growth Corporation, in September 2015. Established in 2009, the firm maintains its corporate headquarters in Smiths Falls, Canada.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 225 | 206 | 193 | 220 | 252 | 380 | 413 | 300 | 173 | |
| Cost of Goods Sold Incl. D&A | 170 | 156 | 136 | 160 | 300 | 529 | 362 | 324 | 105 | |
| Gross Profit | 56 | 50 | 57 | 60 | -48 | -150 | 51 | -24 | 68 | |
| Selling, General and Administrative Excl. Other | 97 | 89 | 87 | 134 | 226 | 288 | 395 | 652 | 462 | |
| Research and Development | 0 | 0 | 1 | 3 | 16 | 26 | 43 | 46 | 12 | |
| Other Operating Expense | 33 | 14 | 53 | 93 | 1,702 | 350 | 551 | 533 | 16 | |
| Operating Income | -74 | -53 | -84 | -170 | -1,992 | -813 | -938 | -1,255 | -469 | |
| Interest Expense | 29 | 28 | 54 | 78 | 96 | 83 | 6 | 5 | 14 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -102 | -110 | -291 | -102 | -250 | 683 | -326 | 125 | -58 | |
| Net Income Before Taxes | -207 | -190 | -429 | -350 | -2,337 | -214 | -1,271 | -1,134 | -541 | |
| Income Taxes | -1 | 0 | 5 | 9 | -4 | -7 | -10 | -91 | 3 | |
| Consolidated Net Income | -208 | -190 | -430 | -487 | -2,483 | -248 | -1,317 | -993 | -562 | |
| Net Income From Continuing Operations | -208 | -190 | -434 | -359 | -2,333 | -207 | -1,261 | -1,043 | -543 | |
| Net Income | -208 | -190 | -430 | -487 | -2,483 | -248 | -1,317 | -993 | -562 | |
| EPS (Recurring) | -0.63 | -0.64 | -3.97 | -4.80 | -53.54 | -6.15 | -3.36 | -2.98 | -1.52 | |
| EPS (Basic, Before Extraordinaries) | -0.63 | -0.64 | -3.97 | -4.80 | -53.54 | -6.15 | -3.36 | -2.98 | -1.52 | |
| EPS (Diluted) | -0.63 | -0.64 | -3.97 | -6.52 | -53.54 | -6.15 | -3.36 | -2.93 | -1.52 | |
| EBITDA | -149 | -136 | -345 | -232 | -2,181 | -42 | -339 | -1,035 | -433 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.64 | 13.73 | 0.51 | 4.00 | 3.19 | 7.78 | 290.83 | 168.23 | 847.34 | |
| Gross Margin | 24.89 | 24.27 | 29.53 | 27.27 | -19.05 | -39.47 | 12.35 | -8.00 | 39.31 | |
| Operating Margin | -32.89 | -25.73 | -43.52 | -77.27 | -790.48 | -213.95 | -227.12 | -418.33 | -271.10 | |
| Net Margin | -92.44 | -92.23 | -222.80 | -221.36 | -985.32 | -65.26 | -318.89 | -331.00 | -324.86 | |
| Shares Outstanding | 385 | 2,980 | 108 | 102 | 46 | 39 | 375 | 350 | 338 | |
| Market Capitalization | 369 | 2,829 | 98 | 880 | 805 | 2,956 | 120,113 | 50,470 | 146,591 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Yanofsky Theresa | Director | Jun 26 '26 | Sale | 0.92 | 15,054 | 13,905 | 146,415 | Jun 29 |
| ATKINS M SHAN | Director | Jun 26 '26 | Sale | 0.92 | 3,197 | 2,953 | 146,517 | Jun 29 |
| Lazzarato David Angelo | Director | Jun 26 '26 | Sale | 0.92 | 22,674 | 20,944 | 211,859 | Jun 29 |
| BAYERN JOSEPH | Director | Jun 26 '26 | Sale | 0.92 | 3,197 | 2,953 | 145,127 | Jun 29 |
| Stewart Thomas Carlton | See Remarks | Jun 17 '26 | Sale | 0.97 | 9,285 | 9,045 | 616,398 | Jun 22 |
| Gedeon Christelle | See Remarks | Jun 17 '26 | Sale | 0.97 | 58,994 | 57,466 | 705,506 | Jun 22 |
| Mongeau Luc | Chief Executive Officer | Jun 17 '26 | Sale | 0.97 | 135,231 | 131,729 | 1,723,913 | Jun 22 |
| Yanofsky Theresa | Director | Mar 31 '26 | Sale | 0.93 | 10,373 | 9,647 | 53,145 | Apr 02 |
| ATKINS M SHAN | Director | Mar 31 '26 | Sale | 0.93 | 2,074 | 1,929 | 41,390 | Apr 02 |
| BAYERN JOSEPH | Director | Mar 31 '26 | Sale | 0.93 | 2,658 | 2,472 | 40,000 | Apr 02 |
| Lazzarato David Angelo | Director | Mar 31 '26 | Sale | 0.93 | 15,624 | 14,530 | 72,048 | Apr 02 |
| Mongeau Luc | Chief Executive Officer | Feb 11 '26 | Sale | 1.06 | 9,376 | 9,951 | 802,992 | Feb 12 |
| Yanofsky Theresa | Director | Dec 31 '25 | Sale | 1.13 | 10,434 | 11,790 | 63,518 | Jan 02 |
| Lazzarato David Angelo | Director | Dec 31 '25 | Sale | 1.13 | 15,715 | 17,758 | 87,672 | Jan 02 |
| ATKINS M SHAN | Director | Sep 29 '25 | Sale | 1.58 | 2,216 | 3,501 | 43,464 | Sep 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.